Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: Relevance to Parkinson's disease

Experimental Neurology

Volumn 203, Issue 2, 2007, Pages 512-520

  Zeevalk, G D ^a   Manzino, L ^a   Sonsalla, P K ^a   Bernard, L P ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Glutathione ethyl ester; Neurodegeneration; Neuroprotection; Oxidative stress

Indexed keywords

3 MERCAPTOPROPIONIC ACID; DOPAMINE; GLUTATHIONE; GLUTATHIONE ETHYL ESTER; MALONIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE);

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN MITOCHONDRION; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MESENCEPHALON; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN CHEMISTRY; CELL COUNT; CELL MEMBRANE; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTATHIONE; HALF-LIFE; INJECTIONS, INTRAVENTRICULAR; MITOCHONDRIA; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TYROSINE 3-MONOOXYGENASE;

EID: 33846418007     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.09.004     Document Type: Article

References (43)

1. Alam Z.I., Daniel S.E., Lees A.J., Marsden C.D., Jenner P., and Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's disease but not incidental Lewy body disease. J. Neurochem. 69 (1997) 1326-1329
2. Anderson M.E., and Lou J.L. Glutathione therapy: from prodrugs to genes. Semin. Liver Dis. 18 (1998) 415-424
3. Anderson M.E., Powrie F., Puri R.N., and Meister A. Glutathione monoethyl ester: preparation, uptake by tissues and conversion to glutathione. Arch. Biochem. Biophsy. 239 (1985) 538-548
4. Boyd-Kimball D., Sultana R., Abdul H.A., and Butterfield D.A. Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against AB(1-42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. 79 (2005) 700-706
5. Cornford E.M., Braun L.D., Crane P.D., and Oldendorf W.H. Blood-brain barrier restriction of peptides and the low uptake of enkephalins. Endocrinology 103 (1978) 1297-1303
6. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., Lees A.J., Jenner P., and Marsden C.D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9 (1994) 92-97
7. Dexter D.T., Sian J., Rose S., Hindmarsh J.G., Mann V.M., Cooper J.M., Wells F.R., Daniel S.E., Lees A.J., Schapira A.H.V., Jenner P., and Marsen C.D. Indexes of oxidative stress and mitochondrial-function in individuals with incidental Lewy body disease. Ann. Neurol. 35 (1994) 38-44
8. Dolphin D., Poulson R., and Avramovic O. Glutathione: Chemical, Biochemical and Medical Aspects (1989), Wiley, New York 22-23
9. Echtay K.S., Winkler E., and Klingenberg M. Coenzyme Q is an obligatory cofactor for uncoupling protein function. Nature 408 (2000) 609-613
10. Echtay K.S., Roussel D., St-Pierre J., Jekabsons M.B., Cadenas S., Stuart J.A., Harper J.A., Roebuck S.J., Morrison A., Pickering S., Clapham J.C., and Brand R.M. Superoxide activates mitochondrial uncoupling proteins. Nature 415 (2002) 96-99
11. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol. 32 (1992) S128-S132
12. Gale G.R., Smith A.B., Atkins L.M., Jones M.M., Singh P.K., and Meredith M.J. Glutathione status, glutathione monoisopropyl ester, and cadmium metabolism in mice. Res. Commun. Chem. Pathol. Pharmacol. 70 (1990) 71-91
13. Gillissen A., Joworska M., Orth M., Coffiner M., Maes P., App E.M., Cantin A.M., and Schultze-Werninghaus G. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respiratory Medicine 91 (2006) 159-168
14. Jenner P., Dexter D.T., Sian J., Schapira A.H.V., and Marsden C.D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann.Neurol. 32 (1992) S82-S87
15. Kannan R., Kuhlenkamp J.F., Jeandidler E., Trinh H., Ookhtens M., and Kkaplowitz N. Evidence for carrier-mediated transport of glutathione across the blood brain barrier in the rat. J. Clin. Invest. 85 (1990) 2009-2013
16. Korf J., and Venema K. Amino acids in the substantia nigra of rats with striatal lesions produced by kainic acid. J. Neurochem. 40 (1983) 1171-1173
17. Lomaestro B.M., and Malone M. Glutathione in health and disease: pharmacotherapeutic issues. Ann. Pharmacother. 29 (1995) 1263-1273
18. Magnani M., Novelli G., and Palloni R. Human plasma glutathione oxidation in normal and pathological conditions. Clin. Physiol. Biochem. 2 (1984) 287-290
19. McLellan L., Lewis A.D., Hall D.J., Ansell J.D., and Wolf C.R. Uptake and distribution of N-acetylcysteine in mice: tissue specific effects on glutathione concentrations. Carcinogenesis 16 (1995) 2099-2166
20. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther. 51 (1991) 155-194
21. Munoz A.M., Rey P., Soto-Otero R., Guerra M.J., and Labandeira-Garcia J.L. Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. J. Neurosci. Res. 76 (2004) 551-562
22. Ogita K., Enomoto R., Nakahara F., Ishitsubo N., and Yoneda Y. A possible role of glutathione as an endogenous agonist at the N-methyl-d-aspartate recognition domain in rat brain. J. Neurochem. 64 (1995) 1088-1096
23. Olney J.W., Zorumski C., Price M.T., and Labruyere J. l-cysteine, a bicarbonate-sensitive endogenous excitotoxin. Science 248 (1990) 596-599
24. Papucci L., Schiavone N., Witort E., Donnini M., Lapucci A., Tempestini A., Formigli L., Zecchi-Orlandini S., Oriandini G., Carella G., Brancato R., and Capaccioli S. Coenzyme Q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. 278 (2003) 28220-28228
25. Park S.-W., Kim S.-H., Park K.-H., Kim S.-D., Kim J.-Y., Baek S.-Y., Chung B.-S., and Kang C.-D. Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci. Lett. 3633 (2004) 243-246
26. Parker W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26 (1989) 719-733
27. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, Orlando
28. Perry T.L., and Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67 (1986) 269-274
29. Puka-Sundvall M., Eriksson P., Nilsson M., Sandberg M., and Lehmann A. Neurotoxicity of cysteine: interaction with glutamate. Brain Res. 705 (1995) 65-70
30. Sanchez-Ramos J., Overvik E., and Ames B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigrostriatum of Parkinson's disease brain. Neurodegeneration 3 (1994) 197-204
31. Scaduto Jr. R.C., Gattone V.H., Grotyohann L.W., Wertz J., and Martin L.F. Effect of an altered glutathione content on renal ischemic injury. Am. J. Physiol. 255 (1988) F911-F921
32. Schapira A.H.V., Cooper J.M., and Dexter D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 3 (1989) 1269 (June)
33. Sechi G., Deledda M.G., Bua G., Satta W.M., Deiana G.A., Pes G.M., and Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 20 (1996) 1159-1170
34. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson study group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism. Ann. Neurol. 44 (1998) S160-S166
35. Shults C.W., Oakes D., Kieburtz K., et al. Effects of coenzyme Q10 in early Parkinson's disease. Arch. Neurol. 59 (2002) 1541-1550
36. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia. Ann. Neurol. 36 (1994) 348-355
37. Tsan M.F., White J.E., and Rosano C.L. Modulation of endothelial GSH concentrations: effect of exogenous GSH and GSH monoethyl ester. J. Appl. Physiol. 66 (1989) 1029-1034
38. Wade L.A., and Brady H.M. Cysteine and cystine transport at the blood-brain barrier. J. Neurochem. 37 (1981) 730-734
39. Wang W., and Ballatori N. Endogenous glutathione conjugates: occurrence and biological functions. Pharmacol. Rev. 50 (1998) 335-355
40. Yazdani U., German D.C., Liang C.-L., Manzino L., Sonsalla P.K., and Zeevalk G.D. Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Exp. Neurol. 200 1 (2006) 172-183
41. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., and Mizuno K. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. 93 (1996) 2713
42. Zeevalk G.D., and Bernard L.P. Energy status, oxidative stress and ubiquitin proteasomal function during chronic and acute complex I inhibition with rotenone in mesencephalic cultures. Antioxid. Redox Signal. 7 (2005) 662-672
43. Zeevalk G.D., Bernard L.P., and Nicklas W.J. Oxidative stress during energy impairment in mesencephalic cultures is not a downstream consequence of a secondary excitotoxicity. Neuroscience 96 (2000) 309-316